A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
| Condition(s) | Advanced Solid Tumor |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year. |
| Who can participate | Inclusion Criteria: 1. They voluntarily signed the informed consent form (ICF) and completed the study procedure and follow-up examination and treatment. 2. Age from 18 to 75 years old, regardless of gender; 3. The ECOG performance status score was 0-1. 4. Advanced solid tumors positive for PAN-CK, confirmed histopathologically or cytologically: Advanced solid tumors that have failed previous standard therapy (disease progression or intolerance), currently have no standard treatment options, or are unable to receive current standard treatment for other reasons Included, but not limited to, driver gene negative non-small cell lung cancer (NSCLC) (except neuroendocrine tumors or mixed types containing \>10% of neuroendocrine tumors), primary or metastatic breast cancer (TNBC), and histopatho |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Aeonvital Biomedicine |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2024-04-08 |
| NCT ID | NCT06257680 |
| Official listing | https://clinicaltrials.gov/study/NCT06257680 |